中国生物制药ADR(SBHMY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SBHMY 中国生物制药ADR

未开盘 02-09 14:31:36 EST 延时

{"stockData":{"symbol":"SBHMY","market":"US","secType":"STK","nameCN":"中国生物制药ADR","latestPrice":15.89,"timestamp":1770665496252,"preClose":15.89,"halted":0,"volume":64,"delay":15,"changeRate":0,"floatShares":457950931,"shares":910273459,"eps":0.524054,"marketStatus":"未开盘","change":0,"latestTime":"02-09 14:31:36 EST 延时","open":15.89,"high":15.89,"low":15.89,"amount":1131.1999999999998,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.524054,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770714000000},"marketStatusCode":0,"adr":0,"adrRate":20,"exchange":"PINK LIMITED","adjPreClose":15.89,"volumeRatio":0.640001},"requestUrl":"/m/hq/s/SBHMY","defaultTab":"news","newsList":[{"id":"2606016224","title":"中国生物制药慢乙肝1类新药Ⅱ期临床达主要终点，为低病毒血症提供新方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2606016224","media":"正大制药订阅号","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606016224?lang=zh_cn&edition=full","pubTime":"2026-01-27 07:01","pubTimestamp":1769468467,"startTime":"0","endTime":"0","summary":"近日，中国生物制药核心企业正大天晴宣布，其针对慢性乙型肝炎病毒感染的口服1类新药——核心蛋白变构调节剂TQA3605在Ⅱ期临床研究中达到主要研究终点。临床现有抗病毒药物如核苷（酸）类药物可以有效抑制HBV复制，但部分患者仍存在应答不佳及低病毒血症，危害不容忽视。此外，低病毒血症患者的疾病进展风险更高，肝细胞癌发生率是病毒完全抑制者的2-4倍甚至更高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012707062897a37ab8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012707062897a37ab8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","IE00BZ08YR35.GBP","BK1191","BK1521","01177","BK1589","SBHMY","HK0000165453.HKD","IE00BZ08YS42.EUR","IE00BZ08YT58.USD"],"gpt_icon":0},{"id":"2594235936","title":"中国生物制药获副总裁兼执行董事谢炘增持100万股 每股作价约6.41港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2594235936","media":"新浪网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594235936?lang=zh_cn&edition=full","pubTime":"2025-12-25 08:18","pubTimestamp":1766621894,"startTime":"0","endTime":"0","summary":"热点栏目自选股数据中心行情中心资金流向模拟交易客户端香港联交所最新资料显示，12月24日，副总裁兼执行董事谢炘增持中国生物制药100万股，每股作价6.4068港元，总金额为640.68万港元。增持后最新持股数目约为3.61亿股，最新持股比例为1.92%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225102536a47593c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225102536a47593c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SBHMY","BK4007"],"gpt_icon":0},{"id":"2593804455","title":"热搜第一！“进口抗癌假药”1500元一盒，有效成分却为0","url":"https://stock-news.laohu8.com/highlight/detail?id=2593804455","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593804455?lang=zh_cn&edition=full","pubTime":"2025-12-22 21:27","pubTimestamp":1766410055,"startTime":"0","endTime":"0","summary":"经检测发现，该版本药品中安罗替尼的含量为0，即“境外版”安罗替尼本质上是完全没有有效成分的假药。该药物在国内流通后，因下游层层加价，一般患者购买的价格在1500元左右一盒，每盒的药量是正版的三倍。公安机关将患者家属提供的剩余药品送至鉴定机构检测，鉴定结论和上述药企的结论一致，即该安罗替尼“仿制药”中未检出安罗替尼成分。由此，连云港市市场监督管理局认定，涉案相关药品可以认定为假药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222230225a46afb02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222230225a46afb02&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1589","HK0000165453.HKD","BK1191","BK1521","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","01177","IE00BZ08YT58.USD","SBHMY"],"gpt_icon":0},{"id":"2579462065","title":"利好密集来袭！创新药概念大爆发","url":"https://stock-news.laohu8.com/highlight/detail?id=2579462065","media":"东方财富研究中心","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579462065?lang=zh_cn&edition=full","pubTime":"2025-10-31 17:54","pubTimestamp":1761904444,"startTime":"0","endTime":"0","summary":"据证券时报报道，今年国家医保谈判在延续医保目录常规调整机制的基础上，首次正式引入“商保创新药目录”机制。此外，年内国产创新药“出海”进程明显提速。根据医药魔方NextPharma数据库，截至10月21日，中国创新药今年对外许可共发生115起，金额总计达到1012.4亿美元，远超2024年全年的519亿美元。国信证券指出，中国创新药产业已经体现出长期向好的发展趋势，并在近年集中体现在BD交易的爆发式增长。配置上，看好创新药长期逻辑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031180526a47fc459&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031180526a47fc459&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09995","SBHMY","BK4007","02552","03759","06990","01952"],"gpt_icon":0},{"id":"2575288909","title":"中国生物制药(1177HK)：PDE3/4抑制剂II期临床数据亮眼 市场潜力巨大","url":"https://stock-news.laohu8.com/highlight/detail?id=2575288909","media":"招银国际","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575288909?lang=zh_cn&edition=full","pubTime":"2025-10-13 00:00","pubTimestamp":1760284800,"startTime":"0","endTime":"0","summary":"中国生物制药在欧洲呼吸学会2025 年会上公布了其PDE3/4 抑制剂TQC3721 的II 期临床结果，临床结果显示TQC3721 可快速改善患者肺功能和症状。临床数据表明TQC3721 具备同类最佳潜力。PDE3/4 药物市场潜力巨大，竞争格局良好。默沙东在今年7 月宣布以100 亿美元收购Verona，体现PDE3/4 抑制剂巨大的市场潜力。作为全球进度第二且唯一处在III 期临床的PDE3/4 抑制剂，我们认为TQC3721 具备重磅海外授权潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101310413494c5896a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101310413494c5896a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SBHMY","BK4007"],"gpt_icon":0},{"id":"2571800933","title":"大健康行业周报 |13亿，“中国美敦力”完成交割；东星医疗：拟以支付现金方式购买武汉医佳宝90%的股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2571800933","media":"保观","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571800933?lang=zh_cn&edition=full","pubTime":"2025-09-29 12:04","pubTimestamp":1759118650,"startTime":"0","endTime":"0","summary":"保观 |聚焦保险创新国内篇行业动态13亿，“中国美敦力”完成交割近日，上海生物医药并购基金携手浦东创投集团旗下引领区基金，完成收购日本大冢集团所持微创医疗股份的交割，交易金额达13亿元人民币，上海生物医药并购基金成为微创医疗重要战略股东，持股约7.3%。此次交割完成后，被视为“中国美敦力”的微创医疗股价在港股市场表现活跃，市值突破200亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929123929a44b6c21&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929123929a44b6c21&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","LU2039709279.SGD","BK1197","LU1152091754.HKD","LU1251922891.USD","02196","BK1515","LU1226287875.USD","LU1008478684.HKD","03320","LU0326950275.SGD","01093","LU0067412154.USD","IE00B031HY20.USD","BK1191","00570","LU1960683339.HKD","IE0008369823.USD","LU1969619763.USD","SBHMY","LU0588546209.SGD","01276","IE00BZ08YR35.GBP","IE0008368742.USD","LU0359201885.HKD","LU2543165471.USD","LU1719994722.HKD","BK1500","03692","LU1226288253.USD","LU1226288170.HKD","03933","LU1303224171.USD","BK1606","IE00B5MMRT66.SGD","IE00B543WZ88.USD","SG9999004220.SGD","LU2328871848.SGD","IE00BZ08YS42.EUR","LU1152091168.USD","LU1226287792.SGD","01177","00874","06160","BK1570","LU1993786604.SGD","LU1023057109.AUD","LU1226287529.USD","LU1328277881.USD","LU0072913022.USD","LU0315179316.USD"],"gpt_icon":0},{"id":"2571782687","title":"华源证券-医药行业周报信立泰：全面布局CKM管线，创新出海加速推进-250928","url":"https://stock-news.laohu8.com/highlight/detail?id=2571782687","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571782687?lang=zh_cn&edition=full","pubTime":"2025-09-28 23:02","pubTimestamp":1759071720,"startTime":"0","endTime":"0","summary":"全面布局CKM管线，创新出海加速推进。我们认为信立泰创新研发已经迎来重大蜕变，公司全面布局心血管-肾脏-代谢慢病领域，在研管线涵盖高血压、血脂异常、心衰、代谢、肾科等多个领域，并布局单抗、多抗、ADC、多肽、环肽、基因编辑等新型技术平台，多款产品已经进入到临床阶段，不断强化公司在中国慢病领域综合性龙头地位。我们看好信立泰基于心血管为核心的CKM创新管线布局，带动公司成长为中国综合性慢病领域创新药龙头。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092900142997af3c80&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092900142997af3c80&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","LU1226287529.USD","LU1328277881.USD","BK1191","LU0326950275.SGD","LU2543165471.USD","BK1583","IE00B543WZ88.USD","LU2039709279.SGD","LU1960683339.HKD","IE00BZ08YT58.USD","LU1152091754.HKD","LU0067412154.USD","LU1226288253.USD","LU1226287792.SGD","09926","01093","LU0501845795.SGD","LU0072913022.USD","IE0008368742.USD","IE00B5MMRT66.SGD","IE00BZ08YS42.EUR","LU0359201612.USD","BK1161","LU0315179316.USD","03692","01177","BK1515","LU1226288170.HKD","LU0314109678.HKD","SBHMY","IE00B031HY20.USD","BK1521","IE0008369823.USD","IE00BZ08YR35.GBP","01276","LU0880133367.SGD","LU1807302812.USD","LU1951186391.HKD","LU1813983027.USD","LU0140636845.USD","BK1574","BK1589","LU0359201885.HKD","LU0359202008.SGD","LU1152091168.USD","LU1226287875.USD","SG9999004220.SGD","LU1023057109.AUD","LU1993786604.SGD","LU1008478684.HKD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":0.1201},{"period":"1month","weight":-0.0113},{"period":"3month","weight":0.2931},{"period":"6month","weight":0.5235},{"period":"1year","weight":0.6487},{"period":"ytd","weight":1.1867}],"description":"中国生物制药有限公司是一间主要从事药品业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂产品及西药产品业务。投资分部主要从事长期及短期投资。其他分部主要从事相关医疗及医院业务。","exchange":"PINK LIMITED","name":"中国生物制药ADR","nameEN":"Sino Biopharmaceutical Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药ADR(SBHMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药ADR(SBHMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药ADR,SBHMY,中国生物制药ADR股票,中国生物制药ADR股票老虎,中国生物制药ADR股票老虎国际,中国生物制药ADR行情,中国生物制药ADR股票行情,中国生物制药ADR股价,中国生物制药ADR股市,中国生物制药ADR股票价格,中国生物制药ADR股票交易,中国生物制药ADR股票购买,中国生物制药ADR股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药ADR(SBHMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药ADR(SBHMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}